Medical Chronicle May 2017 | Page 25

CLINICAL GASTROENTEROLOGY GORD VS HEARTBURN: KNOW THE DIFFERENCE Gastro-oesophageal reflux disease (GORD) isn’t just heartburn or bad indigestion. GORD (or GERD in the US) affects up to 40% of the population in Western countries. Dr Eduan Deetlefs, Gastroenterologist at Mediclinic Milnerton, explains that GORD occurs when the stomach content refluxes past the lower oesophageal sphincter up into the oesophagus and even all the way into the throat or mouth. Experiencing this kind of reflux occasionally is normal. However, over long periods of time, it could be a sign of GORD. “GORD develops when the lower oesophageal sphincter is more open than it should be or if there is a hiatus hernia,” says Dr Deetlefs. “Factors that can lead to a weakened, relaxed or open valve are: Increased pressure in the stomach due to obesity, overeating or pregnancy, certain foods that can cause relaxation of the valve, and certain medications.” As with many other diseases, not everyone experiences the condition in the same way. Some patients have regurgitation and the burning sensation in the centre of the chest known as heartburn, while others develop atypical symptoms such as upper abdominal pain and a vague chest discomfort, says Dr Deetlefs. Sometimes, patients even experience the pain and symptoms of GORD as similar to that of a heart attack. The condition is most commonly diagnosed by gastroscopy. acid the stomach produces. If severe regurgitation still occurs after medication, surgery is an option. During a laparoscopic Nissen fundoplication, the lower oesophageal sphincter is strengthened, usually by wrapping part of the stomach around itself to create a new va lve. The surgery requires a two- or three-day hospital stay, and patients can be back at work within a week or two. Fortunately, surgery is rarely required. Source: Mediclinic Infohub Bring back the with… Packed in 30’s Effective in relieving GORD symptoms 1 Achieves better and quicker healing rates of erosive esophagitis, when compared to other PPIs 1 Improves health-related quality of life 1 Is well tolerated 2 AETIOLOGY Reimbursed by ALL medical aids 3 According to Dr Deetlefs, a diet high in spicy foods, fat and alcohol can most certainly contribute to the development of GORD - although patients can still develop it even if they’re perfectly healthy. It can ‘run in the family’, but researchers aren’t sure yet if that’s because families tend to eat the same foods or whether it’s in the genes. TREATMENT There are three options, depending on the severity of the disease. Getting healthy is a good place to start, although Dr Deetlefs says making lifestyle changes is helpful for some patients, but not all. Healthy changes include regular exercise, losing weight if necessary, quitting smoking, and adjusting what and how much you eat. If these measures don’t ease symptoms, medication may be necessary. Proton pump inhibitors (PPIs) regulate the amount of hydrochloric References: 1. Kalaitzakis E, Björnsson E. A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD). Therapeut & Clin Risk Management 2007;3(4):653-663. 2. Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of Ulcers by Esomeprazole in At-Risk Patients Using Non-Selective NSAIDs and COX-2 Inhibitors. Am J Gastroenterol 2006;101:701-710. 3. Data on File: Ranbaxy (SA) (Pty) Ltd. S4 Nexipraz ® 20 Gastro-resistant tablets. Reg. No. 45/11.4.3/0125. Each gastro-resistant tablet contains esomeprazole magnesium 20,7 mg equivalent to esomeprazole 20 mg. Contains sugar. S4 Nexipraz ® 40 Gastro-resistant tablets.Reg. No. 45/11.4.3/0126. Each gastro-resistant tablet contains esomeprazole magnesium 41,4 mg equivalent to esomeprazole 40 mg. Contains sugar. For full prescribing information please refer to the package insert approved by the medicines regulatory authority. Applicant: Ranbaxy (SA) (Pty) Ltd, a SUN PHARMA company, Ground Floor, Tugela House, Riverside Office Park, 1303 Heuwel Avenue, Centurion, 0046.Tel: +27 12 643 2000. Fax: +27 12 643 2001. www.sunpharma.com. 17117 17117 Nexipraz Advert Lady®® A4.indd 1 2015/06/11 8:05 PM MEDICAL CHRONICLE | MAY 2017 25